Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.52 |
| ▸ | MMP9 | P14780 | 4/20 | 0.52 |
| ▸ | MMP14 | P50281 | 2/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP3 | P08254 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP25 | Q9NPA2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756805 | 0.94 | MAPT (0.46) | MMP2MMP9MMP14MMP1MMP3 | |
| SCHEMBL5754752 | 0.93 | MMP2 (0.49) | MMP2MMP9MMP14MMP1MMP3 | |
| SCHEMBL5757436 | 0.93 | MMP2 (0.47) | MMP2MMP9MMP14MMP1MMP3 | |
| SCHEMBL5754992 | 0.93 | MMP2 (0.49) | MMP2MMP9MMP14MMP3MAPT | |
| SCHEMBL5757499 | 0.92 | MMP2 (0.50) | MMP2MMP9MMP14MMP1MMP3 | |
| SCHEMBL6975991 | 0.89 | MMP9 (0.41) | MMP2MMP9MMP14MMP1MMP3 | |
| SCHEMBL5756234 | 0.89 | LDHA (0.40) | MMP2MMP9MMP14MMP1MMP3 | |
| SCHEMBL5754585 | 0.89 | MMP9 (0.41) | MMP2MMP9MMP14MMP1MMP3 | |
| SCHEMBL5756506 | 0.87 | MMP1 (0.44) | MMP2MMP9MMP14MMP1MMP3 | |
| SCHEMBL5757446 | 0.86 | LDHA (0.47) | MMP2MMP9MMP3MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1208092-B1 | SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR | SAMSUNG ELECTRONICS CO LTD (KR) | 2006-06-21 | — | — | EP | disclosed |
| US-6548667-B2 | For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase | SAMSUNG ELECTRONICS CO. LTD. (KR) | 2003-04-15 | — | — | US | disclosed |
| EP-1208092-A4 | SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR | SAMSUNG ELECTRONICS CO LTD (KR) | 2003-01-02 | — | — | EP | disclosed |
| US-20020169314-A1 | Sulfonamide derivative as a matrix metalloproteinase inhibitor | SAMSUNG ELECTRONICS CO. LTD. (KR) | 2002-11-14 | — | — | US | disclosed |
| EP-1208092-A1 | SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001077092-A1 | SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169314-A1 | Sulfonamide derivative as a matrix metalloproteinase inhibitor | MMP9, MMP3, MMP14 | MMP2 8/4885MMP9 1/4885MMP14 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.